A study to evaluate the safety and effectiveness of resomelagon in patients with polymyalgia rheumatica who are in remission using glucocorticoids

2 1

What is this study about?

This study focuses on individuals living with Polymyalgia rheumatica, an inflammatory condition that causes muscle pain and stiffness, particularly in the shoulders and hips. The research involves patients who are currently in remission, meaning their symptoms are under control, while using glucocorticoid medication, which is a type of steroid used to reduce inflammation. The purpose of this study is to explore the safety and effectiveness of a new oral medication called AP1189, which contains the active substance resomelagon.

During the trial, participants will be assigned to receive either AP1189 tablets or a placebo. The study will last for a period of 12 weeks, during which the tablets will be taken once a day. This research aims to see if the new medication can help patients manage their condition and potentially reduce the need for steroid treatments.

Who Can Join the Study?

You must sign and date a consent form, which is a document that explains the study details and your agreement to participate, before any study activities begin.
You must be 50 years of age or older.
You must have been diagnosed with Polymyalgia rheumatica (an inflammatory condition that causes muscle pain and stiffness) following specific medical guidelines.
You must have started taking glucocorticoids (a type of steroid medicine used to reduce inflammation) for your condition at least 4 weeks before the start of the study.
You must be in clinical remission at the start of the study, meaning your symptoms are controlled and a blood test shows low levels of C-Reactive Protein (a marker in the blood that indicates inflammation).
Your C-Reactive Protein level must have been 8 mg/L or higher at the time you were first diagnosed.
You must not have Giant cell arteritis (an inflammation of the lining of your arteries), which will be checked using a vascular ultrasound (an imaging test that uses sound waves to look at blood vessels).
You must be willing and able to follow the study schedule, the treatment plan, and all required procedures.
Women who are able to become pregnant must have a negative pregnancy test during the screening process and again at the start of the study.
Women who can become pregnant and men who are sexually active must use a highly effective method of birth control (such as hormonal pills, an intrauterine device, or a vasectomy) during the study and for 90 days after the last dose, or they must choose to not have sex during that time.

Who Cannot Join the Study?

Having previously used glucocorticoids (a type of steroid medication used to reduce inflammation) to treat giant cell arteritis (a condition involving inflammation of the lining of your arteries).
Currently taking glucocorticoids (steroid medicine) by mouth, through a vein, or by injection to treat any condition other than polymyalgia rheumatica.
Having other types of inflammatory rheumatic diseases, which are conditions where the body’s immune system attacks the joints or muscles, such as rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritis, or gout.
Having symptoms of giant cell arteritis, such as new headaches, pain when touching the temple area, jaw pain while eating, vision changes, or pain in the limbs when walking.
Having non-inflammatory joint or muscle conditions, such as osteoarthritis (wear and tear of the joints) or fibromyalgia (a condition causing widespread muscle pain), if these are severe enough to interfere with the study.
Having gastrointestinal diseases (problems with the stomach or intestines) that might change how the body absorbs or removes medicine.
Having severe or uncontrolled problems with the kidneys (including chronic kidney disease stage 4 or higher), liver, blood, stomach and intestines, metabolism, hormone system, lungs, heart, or nervous system.
Having had malignancy (cancer) in the last 5 years, except for certain types of skin cancer that have been treated or removed.
Having any other medical condition that the doctor believes could make the study unsafe or prevent the medicine from working correctly.
Being pregnant or currently breastfeeding.
Having taken part in another study involving an experimental drug within the last 4 weeks.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Odense University Hospital	Odense	Denmark
Region Midtjylland	Aarhus	Denmark

Trial status

Country	Status	Recruitment Start
Denmark	Not yet recruiting	02.02.2026

Trial locations

Investigated drugs:

Resomelagon

AP1189 is an oral tablet being tested to see how well it works and how safe it is for people with polymyalgia rheumatica who are currently in remission using steroid medications.

Investigated diseases:

Polymyalgia rheumatica

Polymyalgia rheumatica – This condition is an inflammatory disorder that primarily affects the muscles around the shoulders and hips. It often causes significant stiffness and aching in these areas, particularly during the morning. The discomfort can make simple daily movements difficult to perform. Symptoms may fluctuate in intensity over time. The condition typically progresses through periods of increased activity followed by periods of relative calm.

Trial ID:

2026-525343-33-00

Protocol code:

SynAct-CS010

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A study to evaluate the safety and effectiveness of resomelagon in patients with polymyalgia rheumatica who are in remission using glucocorticoids

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?